Pharmaceutical Pricing, Reimbursement Environment in ChinaDecision ResourcesNovember 15, 2006 26 Pages - SKU: DECR1378423 |
| Countries covered: China Given its sizeable population and rapid urbanization, China represents a potentially lucrative market for drug manufacturers. But the lure of marketing drugs in China is tempered by China's pharmaceutical pricing and reimbursement system. Government price controls, extensive retail mark-ups, and wide regional variations in insurance all pose specific challenges for companies looking to enter the Chinese market. Get the Answers You Need to Shape Your Strategy The Chinese government still sets or guides retail prices for all drugs eligible for reimbursement under China's health insurance plans. What challenges do government-imposed retail price cuts present for manufacturers? What difficulties do China's pricing practices pose for Chinese patients? Inclusion on the National Essential Drug List (NEDL) is a key to success in China. What types of drugs are included on the NEDL? How does the government determine pricing for the various product groups that compose the list? What additional constraints affect the retail price of a given drug? When do manufacturers have input on NEDL selection? As the composition of China's rural and urban populations changes, so too does the level and variety of health care available to residents of these regions. What sort of drug reimbursement is provided by China's various insurance schemes? How will emerging insurance plans-including private insurance-affect patients' ability to obtain medical care? Please note, the PDF e-mail from publisher version of this report is for a global site license. |
More China Pricing Reports
The Outlook for Pharmaceuticals in Brazil, Russia, India & China (pdf/xls) by
Espicom Healthcare Intelligence
These leading emerging economies represent a combined pharmaceutical market of US$132.2 billion. How have they emerged from the economic downturn? Where do commercial opportunities exist ...
BRIC: Pricing, Reimbursment, and Regulatory Update by
Datamonitor
Datamonitor’s report BRIC: Pricing, Reimbursement, and Regulatory Update provides an update of changes to pricing, reimbursement and regulation in Brazil, Russia, India and China during ...
BRIC: Pricing, Reimbursement, and Regulatory Update by
Datamonitor
Overview of healthcare expenditure, healthcare systems, drug regulation, healthcare reforms, drug pricing and reimbursement, and intellectual property environments across multiple markets. Countries analyzed include: Brazil, ...
Insomnia China Prescription Drug Sales Data 2010 by
Draco Healthcare Consulting LLC
2011 China Prescription Drug Sales Database provides the following information: 1) 2010 national sales of individual therapeutic area
2) 2010 national sales ...
Senile Dementia China Prescription Drug Sales Data 2010 by
Draco Healthcare Consulting LLC
2011 China Prescription Drug Sales Database provides the following information: 1) 2010 national sales of individual therapeutic area
2) 2010 national sales ...
See all reports like this >>
More China Reports
D&B Country RiskLine Report: China by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Country Report China February 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Country Report China January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
D&B Country Report: China by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Juice – China – a snapshot (2010) by
Mintel - Snapshots
Juice in China by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. The report covers packaged ...
See all reports like this >>
Related Markets
Pricing Reports
- Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Pricing and Reimbursement of the Healthcare System in India - Low Levels of Drug Reimbursement Lead to a High Out-Of-Pocket Expenditure
- The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector
- Pharmaceutical Pricing Strategies – Changing Approaches to Meet Challenging Times
